Therefore, we carried out an extensive evaluation and characterization of all new molecular entities, therapeutic biologics, and gene and cell therapies authorized by the FDA given that 1980. On top of that, we analyzed the approval pathways and regulatory designations in the context in the legislative and regulatory landscape https://lorda083qcv5.wikirecognition.com/user